Primary Pterygia Excision Performed Via Anduze Technique With Mitomycin-C 0.02% Applied to Subconjunctival Space: Review

Saturday, April 18, 2015: 1:41 PM
Room 3 (San Diego Convention Center)
William B. Trattler, MD

To evaluate pterygium excision performed by the Anduze bare scleral approach with 0.02% Mitomycin-C (MMC) injected into the subconjunctival space, and quantify risks and benefits.

Patients underwent primary pterygium surgery with injection of less than 0.01mL of 0.02% MMC into the subconjunctival space at the completion of the excision.

Ongoing study, results of 112 eyes (112 patients) presented, results will be updated. Three month and one year post-operative follow-up demonstrated a 0.018% (2/112) recurrence rate. There were no vision threatening complications to report, and adverse effects were mild 0.098% (11/112). The post-operative complications were easily resolved with topical therapy with the most common complication being pyogenic granuloma.

The results of this clinical review demonstrate that the Anduze bare scleral approach is an effective surgical technique for pteryigium excision. Injection with 0.1mL of MMC directly into the subconjunctival space provides superior results with minimal risk to the patient.